NCT04308304View on ClinicalTrials.gov

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 16, 2021

Primary Completion Date

May 18, 2022

Study Completion Date

May 18, 2022

Conditions
Alzheimer's Disease
Interventions
DRUG

MK-1942

MK-1942 1 mg, 5 mg, and/or 10 mg capsules taken twice daily (BID) by mouth.

DRUG

Donepezil

Donepezil 5 mg and/or 10 mg tablets taken once daily (QD) by mouth.

DRUG

Placebo

Placebo capsule matched to MK-1942 taken BID by mouth.

Trial Locations (4)

30030

iResearch Atlanta ( Site 0005), Decatur

33009

Velocity Clinical Research, Hallandale Beach ( Site 0002), Hallandale

84124

ICON ( Site 0003), Salt Lake City

72758-6442

Woodland Research Northwest, LLC ( Site 0004), Rogers

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04308304 - MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005) | Biotech Hunter | Biotech Hunter